Literatur: Rivaroxaban

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.



  • 1. Abrams PJ and Emerson CR, “Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor,” Pharmacotherapy, 2009, 29(2):167-81. [PubMed 19170587]
  • 2. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al, “Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects,” Circulation, 2011, 124(14):1573-9. [PubMed 21900088]
  • 3. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, et al, “Oral Rivaroxaban for Symptomatic Venous Thromboembolism,” N Engl J Med, 2010, 363(26):2499-510. [PubMed 21128814]
  • 4. Eriksson BI, Borris LC, Friedman RJ, et al, “Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Hip Arthroplasty,” N Engl J Med, 2008, 358(26): 2765-75. [PubMed 18579811]
  • 5. Gulseth MP, Michaud J, Nutescu EA, “Rivaroxaban: An Oral Direct Inhibitor of Factor Xa,” Am J Health Syst Pharm, 2008, 65(16): 1520-9. [PubMed 18693206]
  • 6. Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
  • 7. Kubitza D, Becka M, Voith B, et al, “Safety, Pharmacodynamics, and Pharmacokinetics of Single Doses of BAY 59-7939, an Oral, Direct Factor Xa Inhibitor,” Clin Pharmacol Ther, 2005, 78(4):412-21. [PubMed 16198660]
  • 8. Kubitza D, Becka M, Wensing G, et al, “Safety, Pharmacodynamics, and Pharmacokinetics of BAY 59-7939 -- An Oral, Direct Factor Xa Inhibitor -- After Multiple Dosing in Healthy Male Subjects,” Eur J Clin Pharmacol, 2005, 61(12):873-80. [PubMed 16328318]
  • 9. Lassen MR, Ageno W, Borris LC, et al, “Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty,” N Engl J Med, 2008, 358(26):2776-86. [PubMed 18579812]
  • 10. Mega JL, Braunwald E, Wiviott SD, et al, “Rivaroxaban in Patients With a Recent Acute Coronary Syndrome,” N Engl J Med, 2012, 366(1):9-19. [PubMed 22077192]
  • 11. Patel MR, Mahaffey KW, Garg J, et al, “Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation,” N Engl J Med, 2011, 365(10):883-91. [PubMed 21830957]
  • 12. Skanes AC, Healey JS, Cairns JA, et al, “Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,” Can J Cardiol, 2012, 28(2):125-36. [PubMed 22433576]
  • 13. The EINSTEIN-PE Investigators, “Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism,” New Engl J Med, 2012, 366(14):1287-97. [PubMed 22449293]
  • 14. Turpie AG, “New Oral Anticoagulants in Atrial Fibrillation,” Eur Heart J, 2007, 29(2):155-65. [PubMed 18096568]
  • 15. Turpie AG, Lassen MR, Eriksson BI, et al, "Rivaroxaban for the Prevention of Venous Thromboembolism After Hip or Knee Arthroplasty. Pooled Analysis of Four Studies," Thromb Haemost, 2011, 105(3):444-53. [PubMed 21136019]
  • 16. Manesh R. Patel, M.D., Kenneth W. Mahaffey, M.D., Jyotsna Garg, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365:883-891 [NEJM 1009638]


  top |


© 2022 Prof. Dr. J. Braun